A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents.
BACKGROUND
Many topical agents with similar efficacies are available for the treatment of ocular allergies. In addition to efficacy, comfort is an important criterion because it affects overall patient satisfaction, compliance, and in turn efficacy.


OBJECTIVE
The goal of this study was to compare the comfort profiles of permirolast, ketorolac, cromolyn, and nedocromil ophthalmic solutions using combined results from 2 separate clinical trials.


METHODS
Two clinical trials were conducted. Adults with asymptomatic eyes were included in the first study. In this single-center, 7-day, prospective, double-blind, single-dose, crossover, parallel-group study, subjects were randomized to be bilaterally dosed with pemirolast, cromolyn, or ketorolac at each of 3 visits. Study 2 was a single-center, 1-day, prospective, randomized, double-blind, single-dose, contralateral, active-control study in which subjects received pemirolast in 1 eye and nedocromil in the contralateral eye. In both studies, subjects completed a pre- and postinstillation ocular comfort questionnaire: the primary variable was overall ocular discomfort, measured on a 4-point scale original to these studies (0 = absent, 1 = mild, 2 = moderate, 3 = severe). Half-increments were permitted. Secondary variables included burning/stinging, foreign-body sensation, tearing, and photophobia.


RESULTS
Forty-five subjects (29 women, 16 men; mean [SD] age, 35.9 [12.6] years) were enrolled in study 1; 48 subjects (30 women, 18 men; mean [SD] age, 33.6 [10.2] years) were enrolled in study 2. In study 1, overall discomfort was significantly lower with pemirolast than with cromolyn (P = 0.001) or ketorolac (P < 0.001). In terms of overall discomfort, the number of subjects with a clinically significant increase (>/=1 unit) in score was significantly lower with pemirolast compared with ketorolac (P = 0.021). Burning/stinging and tearing were also significantly lower with pemirolast than with cromolyn (P < 0.001 and P = 0.014, respectively). Mean changes in score compared with preinstillation were consistently lower with pemirolast than with cromolyn for both burning/stinging (P < 0.001) and tearing (P = 0.014). In study 2, overall discomfort was significantly lower with pemirolast than with nedocromil (P < 0.001). The number of subjects with a clinically significant increase in overall discomfort score was significantly lower with pemirolast than with nedocromil (P = 0.007). No changes in ocular tolerability parameters were reported in either study.


CONCLUSIONS
In these single-dose studies, pemirolast was found to be significantly more comfortable than cromolyn, ketorolac, or nedocromil.
Shulman
David G
DG
University of Texas Health Science Center, Audie Murphy Veterans' Administration Hospital, San Antonio, Texas, USA
Amdahl
Larry
L
Washington
Camisha
C
Graves
Adrienne
A
D000287:Administration, Topical; D000328:Adult; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D004205:Cromolyn Sodium / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006633:Histamine Antagonists / Q000627:therapeutic use*; D006801:Humans; D020910:Ketorolac / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017835:Nedocromil / Q000627:therapeutic use; D009883:Ophthalmic Solutions; D010349:Patient Compliance; D011725:Pyridines / Q000627:therapeutic use; D011744:Pyrimidinones / Q000627:therapeutic use; D016896:Treatment Outcome
D018926:Anti-Allergic Agents; D006633:Histamine Antagonists; D009883:Ophthalmic Solutions; D011725:Pyridines; D011744:Pyrimidinones; D017835:Nedocromil; C055139:pemirolast; D004205:Cromolyn Sodium; D020910:Ketorolac